Opdivo (nivolumab)

November 29, 2016November 29, 2016

Opdivo Approved in EU for Certain Advanced Classical Hodgkin’s Lymphoma Patients

News

The European Commission has approved the immunotherapy agent Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL) following autologous stem cell transplant (ASCT) ... Read more

November 23, 2016

Immune Checkpoint Inhibitor Shows Promise for Lymphoma, Other Cancers

News

The immune checkpoint inhibitor BMS-986016 has shown promising results in patients with multiple hematological and solid malignancies either alone or in combination with Opdivo (nivolumab), according to interim results from two ... Read more

November 7, 2016November 7, 2016

Bristol-Myers to Present Data on New Immunotherapy Combo to Treat Lymphoma

News

Bristol-Myers Squibb will present new data on the potential of its immunotherapy agent Opdivo (nivolumab) in combination with Yervoy (ipilimumab), and combinations with or without Opdivo of other investigational immunotherapies, to treat various cancers. ... Read more

October 27, 2016October 27, 2016

New Report Supports Opdivo for Relapsed Hodgkin’s Lymphoma Patients

News

Bristol-Myers Squibb recently presented data supporting the use of Opdivo (nivolumab) in a subgroup of patients with classical Hodgkin’s lymphoma who had undergone a prior stem cell transplant and treatment with ... Read more